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Smad3of BK virus (BKV)-associated diseases in immunosuppressed patients has
prompted an investigation of the immune response to BKV, especially the role of cytokines in regulating viral
replication. We examined the effect of TGF-β, a cytokine that is stimulated by certain immunosuppressive
therapies, on BKV gene expression during lytic infection of renal proximal tubule epithelial cells. Viral gene
expression, and speciﬁcally the activity of the BKV early promoter, is regulated by TGF-β in a strain-
dependent manner. Promoter activity is upregulated in the presence of TGF-β for the TU strain of BKV, and
not for the Dik, Dunlop, or Proto-2 strains. Using site-directed mutagenesis, we have identiﬁed a small
segment of the TU promoter that is required for stimulation in response to TGF-β. These results demonstrate
that BKV strains can respond differently to cytokine treatment and suggest that TGF-βmay play a role in the
reactivation of BKV.
© 2008 Elsevier Inc. All rights reserved.Introduction
BK virus (BKV) is a humanpolyomavirus that has awell-established
role in complications following transplantation and immunosuppres-
sion (Comoli et al., 2006; Nickeleit and Mihatsch, 2006). In particular,
BKV is the causative agent of polyomavirus nephropathy (PVN) in up to
10% of kidney transplant recipients, resulting in loss of graft function in
10–80% of those affected (Hirsch et al., 2006). BKV reactivation is also
associated with hemorrhagic cystitis (HC) in bone marrow transplant
recipients, with approximately 50% of patients with active BKV viruria
progressing to HC (Bedi et al., 1995; Pavlakis et al., 2006). Despite
extensive investigation, there has been limited success in identifying
antiviral treatments for BKV reactivation and lytic infection (Josephson
et al., 2006; Trofe et al., 2006). Typically, upon diagnosis of BKV
reactivation and PVN, the immunosuppressive regimen of the patient
is reduced to allow the immune system to ﬁght the viral infection. This
approach, however, increases the risk of graft rejection. Thus it is
important to investigate the immune response to BKV to identify
immune components that control viral replication.
BKV was ﬁrst isolated from the urine of a kidney transplant patient
with ureteric stenosis in 1971 (Gardner et al., 1971). Primary infection
with BKV occurs early in childhood, with seroconversion occurring by
the age of 10 in up to 80% of the human population (Knowles, 2006).
Following the primary infection, BKV undergoes viremic dissemina-
tion and establishes a lifelong persistent infection primarily in the
cells of the kidney and urinary tract (Chesters et al., 1983; Heritage
et al., 1981). More speciﬁcally, tubular epithelial cells of the kidney and).
l rights reserved.epithelial cells of the urinary tract are major sites of BKV persistence
and reactivation (Doerries, 2006; Nickeleit and Mihatsch, 2006).
BKV has a non-enveloped, icosahedral virion composed of three
proteins, VP1, VP2, and VP3, which encapsidate a circular double-
stranded DNA genome of approximately 5.2 kb. The genome can be
divided into three distinct regions: the early region, which contains
the coding sequences for large tumor antigen (TAg) and small tumor
antigen (tAg); the late region, which contains the coding sequences for
VP1, VP2, VP3, and agnoprotein; and the non-coding control region
(NCCR), which contains the origin of replication and the viral early and
late promoters. The NCCR is used to distinguish one strain of BKV from
another because of the propensity of this region to acquire point
mutations and structural rearrangements (Moens and Van Ghelue,
2005). BKV strains can be divided into two classes: archetypal (pre-
rearranged) strains, presumed to be the infectious and transmissible
virus, and rearranged strains, which are predominately isolated from
tissue biopsy samples (Cubitt, 2006). The NCCRs of archetypal strains
are structurally divided into blocks of transcription factor binding
sites, arbitrarily designated O (142 bp, containing the origin of
replication, TATA box, and TAg binding sites), P (68 bp), Q (39 bp), R
(63 bp), and S (63 bp) (Markowitz and Dynan, 1988; Moens et al.,
1995). Rearranged BKV strains result from the restructuring of the
archetypal NCCR, such that certain blocks (primarily P, Q, and R) are, in
whole or in part, duplicated or deleted (Moens and Van Ghelue, 2005).
It is commonly reported that the predominant NCCR conﬁguration
actively shed in urine is archetypal (Markowitz et al., 1991; Negrini
et al., 1991; Sharma et al., 2007; Sundsfjord et al., 1999; Takasaka et al.,
2004), and that NCCR rearrangements seem to be isolated more
frequently from the tissues and sera of patients with high viral loads
(Boldorini et al., 2001; Gosert et al., 2008; Stoner et al., 2002). In
Fig. 1. TGF-β upregulates BKV TU gene expression during infection. A) RPTE cells were
infected with the indicated strains of BKV at an MOI of 0.5 IU/cell and treated with
10 ng/ml TGF-β at three to four hpi. Total cell protein was harvested at three dpi and
analyzed by Western blot, probing for TAg and GAPDH. Mock, mock-infected samples
with no TGF-β treatment. B) RPTE cells were infected with the TU strain of BKV at an
MOI of 0.5 IU/cell in the presence or absence of 10 ng/ml TGF-β, and total cell RNA was
prepared at 24, 36, 48, 72, and 96 hpi. Relative TAg transcript levels were determined
using real-time RT-PCR, normalizing to levels of GAPDH transcripts in each sample. One
representative experiment is shown; triplicate samples were analyzed in the same
assay. Fold expression of TAg at 24 hpi, untreated was arbitrarily set to one. Mock, mock-
infected samples with no TGF-β treatment.
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culture and these rearrangements enhance the ability of the virus to
replicate and transform cells (Rubinstein et al., 1991; Watanabe and
Yoshiike, 1985, 1986). It is possible that changes in the viral promoter
region can also result in altered pathogenesis, such as a heightened
ability to reactivate or disseminate. Furthermore, rearrangements may
affect the cell tropism of BKV, allowing infection of other cell types in
addition to kidney and urinary epithelial cells. The confounding obser-
vation, however, is that as of yet there is no apparent correlation be-
tween BKV NCCR structure and clinical outcome (Sharma et al., 2007).
TGF-β is a secreted cytokine having three isoforms in mammals
(TGF-β1, TGF-β2, TGF-β3), all with similar functions involved in the
regulation of cell proliferation, differentiation, and immune suppres-
sion (Feng and Derynck, 2005; Li et al., 2006). TGF-β is produced by
many different cell types, including renal epithelial cells, a major site
of BKV reactivation. Interestingly, the expression of TGF-β is enhanced
in the presence of immunosuppressive therapies commonly adminis-
tered to renal transplant patients (Khanna et al., 1999a,b; McMorrow
et al., 2005; Shihab et al., 1996). We hypothesized that TGF-β would
have an upregulatory effect on BKV gene expression and replication,
correlating with the evident reactivation of BKV in kidney transplant
recipients.
TGF-β is initially expressed as an inactive complex of precursor
polypeptides that undergoes activation by proteolytic cleavage. Upon
maturation, TGF-β can bind to TGF-β receptor II dimers, resulting in
the recruitment and phosphorylation of TGF-β receptor I dimers (Shi
and Massague, 2003). Once activated, TGF-β receptor I recruits and
phosphorylates Smad2 and Smad3 proteins, the primary components
of the TGF-β signaling cascade (Massague et al., 2005). Phosphory-
lated Smad2 and Smad3 proteins can then form a complex with
Smad4, resulting in the nuclear translocation of these proteins. This
complex has some weak intrinsic DNA binding activity of its own, but
is more effective in regulating TGF-β-dependent gene expression in
conjunction with cellular transcriptional co-activators that have high
DNA binding activity and speciﬁcity (Brown et al., 2007;Massague and
Wotton, 2000; Shi et al., 1998).
In this report, we characterize the effect of TGF-β on the lytic
infection of BKV in renal proximal tubule epithelial (RPTE) cells and on
the activity of the viral early region promoter. We demonstrate that
the response to TGF-β-mediated regulation is dependent on the strain
of BKV and thus the NCCR structure. We show that upregulation by
TGF-βmaps to a short region of the promoter thatmost likely contains
two distinct transcription factor binding sites. These ﬁndings
demonstrate transcriptional regulation of BKV by a cytokine that is
found at elevated levels in transplant patients.
Results and discussion
TGF-β-mediated regulation of BKV gene expression during infection
We ﬁrst investigated the regulatory potential of TGF-β on BKV gene
expression during lytic infection of RPTE cells. We examined the levels
of TAg at three dpi in cells infected with three strains of BKV that
differ signiﬁcantly in their NCCR structures: TU (O-P-Q-R1–12-P16–68-
Q1–35-R52–63-S), Dunlop (O-P-P1–7;26–68-P1–64-S), and Proto-2 (O-P-
P1–7;26–68-P-Q1–28-S7–63). TGF-β only signiﬁcantly affected the expres-
sion of viral proteins in cells infectedwith the TU strain of BKV, as shown
by the upregulation of TAg levels (Fig. 1A). TAg expression remained
relatively unchanged in cells infected with the Dunlop and Proto-2
strains. To demonstrate that the effect was speciﬁc to viral gene
expression and not a result of TGF-β-mediated inhibition of epithelial
cell proliferation, samples were also analyzed for levels of GAPDH, a
cellular housekeeping gene. These results indicate that the presence of
TGF-β affects BKV gene expression in a strain-speciﬁc manner.
To determine whether TGF-β-mediated regulation occurs during
transcription or translation, we examined the levels of early genetranscripts during the course of BKV TU infection. Total cell RNA was
harvested at 24, 36, 48, 72, and 96 hpi and analyzed by a real-time RT-
PCR assay to detect TAg transcripts in the absence or presence of TGF-
β (Fig. 1B). Results were normalized to the levels of GAPDH mRNA
present in the samples. TGF-β had a prominent effect on TAg tran-
scription at early time points, with 2.5-fold upregulation in transcript
levels at 24 and 36 hpi, and 3.3-fold upregulation over untreated cells
at 48 hpi. At the later stages of infection the effect of TGF-β was less
pronounced, with only 1.8-fold upregulation in TAg transcripts at both
72 and 96 hpi. These results suggest that TGF-β-mediated regulation
occurs at the level of transcription. Furthermore, the timing and
limited duration of the upregulation suggest that transcription factors
involved in the TGF-β signaling cascade are responsible for the effect.
BKV early promoter activity in the presence of TGF-β
We next set out to examine the effect of TGF-β on the viral early
promoter. We cloned the NCCRs of four BKV strains [TU, Dunlop,
Proto-2, Dik (archetypal)] into a luciferase reporter plasmid, such that
the viral early promoter drives the expression of the ﬁreﬂy luciferase
gene. This assay permitted us to examine the effect of TGF-β on
Fig. 2. BKV early promoter activity in the presence of TGF-β. A) RPTE cells were
cotransfected with BKV early promoter-ﬁreﬂy luciferase constructs and a promoterless
control Renilla luciferase plasmid. TGF-β was added at three to four hpt and total cell
lysates were harvested at 48 hpt. Luciferase assays were performed on triplicate
samples and data are represented as relative light units (RLU) of ﬁreﬂy luciferase
activity, normalized to RLU of Renilla luciferase activity. Data shown represent results
obtained from three independent experiments. B) HT-1080 cells were cotransfected
with BKV early promoter-ﬁreﬂy luciferase constructs and a promoterless control Renilla
luciferase plasmid and assayed as described in (A). Data shown represent results
obtained from three independent experiments.
Fig. 3. Alignment of BKV NCCRs. The segments of the NCCRs (TU, Dik, Dunlop, Proto-2) from th
to the O block are shown. The O block is not shown because it is highly homologous between
Underlined regions indicate the predicted Smad3 and ZEB-1 binding sites. Dots indicate nucle
NCCR that does not align anywhere in the Dik, Dunlop, or Proto-2 NCCRs. The early promoter
late promoter is read from right to left (bottom to top), in the direction of the late coding r
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BKV genomic sequences. RPTE cells were cotransfected with the BKV
promoter-driven luciferase plasmids and a promoterless control Re-
nilla luciferase plasmid in the absence or presence of TGF-β, and
lysates were assayed for luciferase activity at 48 hpt (Fig. 2A). The
results conﬁrmed that only the TU early promoter was affected by
TGF-β treatment, while the other three viral promoters showed no
signiﬁcant change in activity in the presence of TGF-β (1.4-, 1.1-, and
1.1-fold change for Dik, Dunlop, and Proto-2 promoters, respectively).
The 2.5-fold upregulation (P=0.009) in TU promoter activity was
similar to that seen during BKV infection of RPTE cells (Fig. 1). The
results of this assay suggest that the effect of TGF-β is mediated solely
at the promoter and is therefore driven by speciﬁc transcription
factors.
The regulation of BKV early promoter activity by TGF-β signaling
may depend on the cell type examined. The luciferase assay described
abovewas also performed in HT-1080 cells, a human ﬁbrosarcoma cell
line (Fig. 2B). The TU and Dik promoters responded similarly to TGF-β
treatment in both cell types: TU promoter activity was upregulated by
3.1-fold (Pb0.001) and Dik activity remained relatively unchanged
(1.6-fold decrease, Pb0.001) in the HT-1080 cells. However, the
Dunlop and Proto-2 promoters were repressed in the presence of TGF-
β in HT-1080 cells by 2.6- and 3.1-fold respectively (Pb0.001 and
P=0.002, respectively). In addition to cells of the kidney and urinary
tract, BKV sequences have been isolated from peripheral blood
mononuclear cells (Chatterjee et al., 2000; Doerries et al., 1994),
tonsils (Goudsmit et al., 1982), and brain (Elsner and Doerries, 1992).
Thus, TGF-β-mediated signaling may differentially regulate BKV
during infections of other cell types.
Having mapped the effect of TGF-β to the BKV promoter, we
wanted to examine the differences between the TU NCCR and the
other three NCCRs used in our studies. We performed an alignment of
the four BKV NCCRs and observed that there was one region (7 bp,
starred nucleotides) of the TU NCCR that did not align to any region of
the Dik, Dunlop, or Proto-2 NCCRs (Fig. 3). We used the MatInspector
transcription factor binding site prediction program (Cartharius et al.,
2005) to analyze the potential binding sites in the viral promoters.
Within this unique sequence in the TU NCCR, the program predicted ae nucleotide before the start codon of agnoprotein through the P block directly adjacent
strains. Bold type indicates nucleotides that are identical in at least three of the strains.
otides not foundwithin a sequence. The starred nucleotides indicate the region of the TU
is read from left to right (top to bottom), in the direction of the early coding region. The
egion.
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probability. There were no predicted ZEB-1 binding sites in the other
three NCCRs. ZEB-1 has been reported to interact with Smad3 and
mediate TGF-β-dependent gene regulation (Postigo, 2003; Postigo
et al., 2003). Interestingly, in both the TU and Dik NCCRs the
MatInspector program also predicted a binding site for the transcrip-
tion factor Smad3 with a high probability. The proximity of the
predicted ZEB-1 site to the predicted Smad3 site in the TU NCCR
suggests that a Smad3–ZEB-1 complex could bind to the promoter and
regulate early gene transcription.
TU promoter sequences required for TGF-β-mediated regulation
We used site-directed mutagenesis to modify the luciferase
plasmids to deﬁne the exact sequences required for TGF-β-dependent
activation of the early promoter (Fig. 4A). Starting with the pGL2-TU
plasmid as a template, we introduced a single base change (C to G) in
the core of the predicted Smad3 binding site, resulting in the pGL2-TU-
Smt plasmid. This mutation has previously been shown to effectively
disrupt the ability of Smad proteins to bind DNA (Jonk et al., 1998). In a
similar manner, we modiﬁed the pGL2-Dik plasmid, which contains a
predicted Smad3 binding site identical to that found in the TU NCCR,
lacks a predicted ZEB-1 binding site, and is not affected by TGF-β. Using
site-directed mutagenesis, we introduced six nucleotides (GGTTTC) to
place a predicted ZEB-1 binding site in the same relative position and
orientation as in the TU NCCR (pGL2-Dik+6TU).
The wildtype and mutated luciferase reporter plasmids were
transfected into RPTE cells in the absence or presence of TGF-β, and
lysates were assayed for luciferase activity at 48 hpt (Fig. 4B). Similar
to previous results, the TU early promoter was upregulated by 2.2-foldFig. 4. Regions of the TU promoter required for TGF-β-mediated regulation of BKV. A)
Schematic representation of promoter constructs. TU-Smt has a single base change in
the core of the predicted Smad3 binding site (hatched). Dik+6TU has a 6 bp insertion
that creates the predicted ZEB-1 binding site. The early promoter is read from left to
right, with the start codon for the ﬁreﬂy luciferase gene following the right end of the
promoter. B) RPTE cells were cotransfected with wildtype or mutant BKV early
promoter-ﬁreﬂy luciferase constructs and a promoterless control Renilla luciferase
plasmid. TGF-β was added at three to four hpt and total cell lysates were harvested at
48 hpt. Luciferase assays were performed on triplicate samples and data are represented
as relative light units (RLU) of ﬁreﬂy luciferase activity, normalized to RLU of Renilla
luciferase activity. Data shown represent results obtained from three independent
experiments.(P=0.009) in the presence of TGF-β, while the Dik promoter showed
little change in activity (1.2-fold increase). The mutant TU promoter
was also unresponsive to TGF-β treatment (1.2-fold decrease), sug-
gesting that the putative Smad3 site is required for TGF-β-dependent
promoter activation and that the putative ZEB-1 site alone is not
sufﬁcient. In addition, the mutant Dik promoter was upregulated by
2.7-fold (P=0.002) in the presence of TGF-β, suggesting that both the
predicted Smad3 and ZEB-1 sites are necessary for upregulation. It is
important to note that the mutations did not signiﬁcantly change the
basal activities of the promoters (Fig. 4B: compare untreated, TU to
TU-Smt; untreated, Dik to Dik+6TU). These results suggest that
regulation depends directly on the presence of binding sites for
transcription factors involved in TGF-β signaling in the viral early
promoter, and that the absence of such sites results in unresponsive-
ness to TGF-β.
The MatInspector binding site predictions and the results of the
luciferase assays strongly suggested that Smad3 and ZEB-1 regulate
the TU promoter. However, our attempts to show Smad3 and ZEB-1
binding to the viral promoter using three different assays, electro-
phoretic mobility shift assay, anchored transcriptional promoter assay
(Ravichandran and Major, 2006), and siRNA-mediated knockdown of
Smad3 and ZEB-1, failed to demonstrate conclusively Smad3 and ZEB-
1 binding to, or activation of, the TUpromoter in the presence of TGF-β
(data not shown). It remains possible that Smad3 is acting with
another transcription factor, or that the assays simply were not well
suited for demonstration of binding of these particular factors in our
system. It will be of interest to deﬁne the nature of the factors
mediating the TGF-β response in the future.
Previous studies have shown the relevance of Smad-dependent
TGF-β signaling during viral infections. For example, JC virus (JCV)-
infected oligodendrocytes have elevated levels of TGF-β, Smad3, and
Smad4, and chloramphenicol acetyl transferase assays demonstrate
the activating effect of Smad protein overexpression on the early and
late viral promoters (Enam et al., 2004). Recently, it was shown that
TGF-β stimulates JCV replication and that MAPK kinase (MEK)
inhibitors can block this effect, indicating a role for activated
downstream transcription factors in TGF-β-mediated upregulation
(Ravichandran et al., 2007). Epstein–Barr virus (EBV), a ubiquitous
human gammaherpesvirus that has both latent and lytic stages of
infection, is also regulated by TGF-β-mediated signaling. Studies have
shown that TGF-β treatment drives the reactivation of EBV lytic
infection from latently-infected B cells (di Renzo et al., 1994) and
epithelial cells (Fukuda et al., 2001). These and other reports have
established the relevance of TGF-β and Smad3 in viral regulation (Li
et al., 2006; Reed, 1999).
Our studies of cytokine-mediated regulation of BKV gene expres-
sion and replication are targeted at understanding the process of viral
reactivation in immunosuppressed transplant patients. Previously, it
has been shown that common immunosuppressive therapies used in
renal transplantation patients, such as cyclosporine and tacrolimus,
result in upregulation of TGF-β expression in various cell types,
including kidney epithelial cells (Khanna et al., 1999a,b; McMorrow
et al., 2005; Shihab et al., 1996). Therefore, we hypothesized that TGF-
β-mediated upregulation of the TU strain of BKV would result in an
enhanced ability to reactivate in renal transplant recipients and,
consequently, an increase in virulence of this particular strain.
However, there are few reports of the TU strain in clinical isolates
(Sundsfjord et al., 1994, 1990), and we have been unable to identify
other naturally occurring strains of BKV that contain both the
sequences in the TU promoter that are required for TGF-β-mediated
activation. Nevertheless, the predicted Smad3 site occurs in a number
of other strains [MAN10B (GenBank accession no. DQ176633), WWT
(M34048), URO1 (U33549), TC-3 (AF164514), AS (M23122), TW-2
(AB213487), SJH85B (DQ176634), T2R.1BKreg-3-4 (AF442893),
SA090600 (AF356532)], and Smad3 is known to have many different
functional binding partners, including AP-1, c-MYC, NF-κB, and SP1
10 J.R. Abend, M.J. Imperiale / Virology 378 (2008) 6–12(Brown et al., 2007), all of which also have binding sites in the NCCR.
The results of the luciferase assays using mutated promoters (Fig. 4)
support the likelihood that there are two transcription factors
involved in regulating the response to TGF-β. Thus, there is potential
for TGF-β-mediated activation or repression of other BKV strains.
Our studies provide evidence for the transcriptional regulation of
BKV early gene expression by as yet unidentiﬁed components of the
TGF-β signaling cascade. However, the postulated contribution of TGF-
β to BKV reactivation in transplant patients must be considered in the
context of the overall immune status of those individuals. Previously,
we also described the inhibition of BKV replication by IFN-γ, in a
strain-independent manner (Abend et al., 2007). It is therefore
reasonable to posit that reactivation of BKV in immunocompromised
patients may require multiple signals, such as the enhancement of
viral gene expression by TGF-β and the absence of IFN-γ-mediated
inhibition of replication, as well as others. Understanding the
contributions of each signal to the outcome of the infection will be
critical for building a complete picture of the interaction between BKV
and the host immune system.
Materials and methods
Cell culture and reagents
Primary human renal proximal tubule epithelial cells (RPTE cells,
Cambrex) were maintained in renal epithelial cell basal medium
(REBM, Cambrex) supplemented with human epidermal growth
factor, fetal bovine serum (FBS), hydrocortisone, epinephrine, insulin,
triiodothyronine, transferrin, and GA-1000 as indicated for renal
epithelial cell growth medium (REGM, supplements obtained as
REGM SingleQuots, Cambrex). HT-1080 cells (ATCC CCL-121) were
maintained in Dulbecco's Modiﬁed Eagle Medium (Gibco) containing
10% FBS (Cambrex), 100 U/ml penicillin, and 100 µg/ml streptomycin
(Cambrex). Both RPTE and HT-1080 cells were grown at 37 °C with 5%
CO2 in a humidiﬁed incubator. Recombinant human TGF-β1, produced
in A293 cells (Peprotech, Inc.), was reconstituted according to the
manufacturer's recommendations and used at a concentration of
10 ng/ml.
Viruses
BKV stocks were prepared from genomic clones of TU (cloned into
the EcoRI site of pGEM-7Zf(−)), and Dunlop and Proto-2 (cloned into
the BamHI site of pBR322, gift of Peter Howley), as previously
described (Abend et al., 2007). The resulting crude viral stocks were
titrated by ﬂuorescent focus assay as previously described (Abend
et al., 2007) and the integrity of theNCCRwas conﬁrmedby sequencing
of PCR products.
Infections
RPTE cells at 70% conﬂuence were infected with the TU, Dunlop, or
Proto-2 strains of BKV in REGM at an MOI of 0.5 IU/cell (infectious
units per cell), incubating for 1 h at 37 °C. Viral lysates used for the
infectionwere replaced with fresh REGM. TGF-βwas added at 3 to 4 h
post-infection (hpi).
Western blotting
Total cell protein was harvested at three days post-infection (dpi)
using E1A lysis buffer (Harlow et al., 1986) supplementedwith 5 μg/ml
PMSF, 5 μg/ml aprotinin, 5 μg/ml leupeptin, 0.05 M sodium ﬂuoride,
and 0.2 mM sodium orthovanadate. The Bio-Rad protein assay was
used to determine the protein concentration of each lysate and 10 μg
of protein were electrophoresed on an 4–20% Tris–glycine polyacry-
lamide gel (Lonza) and analyzed by Western blotting for the expres-sion of viral early protein TAg and GAPDH as previously described
(Abend et al., 2007).
RNA extraction and cDNA synthesis
Total cell RNA was harvested at 24, 36, 48, 72, and 96 hpi using
TRIzol reagent (Invitrogen) according to the manufacturer's instruc-
tions. Samples were treated with DNase I (Promega) to reduce
contaminating DNA, and RNA integrity was conﬁrmed by electro-
phoresis on an agarose gel. To generate cDNA, reverse transcription
reactions were performed on 1 μg of input RNA using the iScript cDNA
Synthesis Kit (Bio-Rad), according to the manufacturer's instructions.
Real-time PCR: TaqMan assay
Primers and probes used to assay TAg and GAPDH transcript levels
were reported previously (Abend et al., 2007). PCR reactions were
performed in a total volume of 25 μl using TaqMan Universal PCR 2x
master mix (Applied Biosystems), 2.5 μl cDNA template, 500 nM of
each primer, and 200 nM probe. The iCycler iQ5 Real-Time Detection
System (Bio-Rad) was used for ampliﬁcation with the following PCR
program: 2 min at 50 °C; 10 min at 95 °C; 40 cycles of denaturation at
95 °C for 15 s and annealing and extension at 56 °C for 1 min. Results
are presented as the fold change in TAg transcript levels, with the
relative level observed at 24 hpi, untreated, arbitrarily set to one.
Results are normalized to the levels of GAPDH transcripts present
using the 2−ΔΔC(T) (Livak) method (Livak and Schmittgen, 2001).
Generation of luciferase constructs
TheNCCRs of four strains of BKVwere ampliﬁed from their genomic
clones using the primers Agno1 (5′ AGTGCTAGCGCCTTTGTCCAGTT-
TAACT 3′) and LTAg2 (5′ AGTCTCGAGAAATAGTTTTGCTAGGCCTCA 3′),
which contain the restriction endonuclease sites for NheI and XhoI,
respectively (underlined). Polymerase chain reactions utilizing these
primers produced 350–400 bp fragments spanning the NCCR from the
start codon of agnoprotein to 35 bp before the TAg start codon. These
fragments were ﬁrst cloned into the pGEM-T Easy vector (Promega)
and then subcloned into the luciferase vector pGL2-basic (Promega) by
means of the NheI and XhoI sites. In these resulting luciferase con-
structs (pGL2-TU, pGL2-Dik, pGL2-Dunlop, pGL2-Proto-2), the BKV
early promoter drives the expression of the ﬁreﬂy luciferase gene.
Site-directed mutagenesis
The following primers were synthesized and HPLC puriﬁed to
introduce a point mutation (underlined) at nucleotide 362 (GenBank
accession no. DQ305492) in the BKV TU NCCR: TU-SmtFOR (5′ TCGCA-
AAACATGTCTGTGTGGCTGCTTTCCGG 3′), TU-SmtREV (5′ CCGGAAAG-
CAGCCACACAGACATGTTTTGCGA 3′). The following primers were
synthesized and HPLC puriﬁed to insert 6 bp normally present only
in the TU NCCR into the BKV Dik NCCR (underlined): Dik+6TUFOR (5′
AAACATGTCTGTCTGGCTGCTTTCCGGTTTCACTCCTTTGG 3′), Dik+
6TUREV (5′ CCAAAGGAGTGAAACCGGAAAGCAGCCAGACAGACATGTTT
3′). Mutagenesis was performed following the protocol for the
QuikChange II Site-Directed Mutagenesis Kit (Stratagene) using the
primer pairs at 1.25 nM each, 100 ng of pGL2-TU or pGL2-Dik as
template, 1 mM dNTPs, and 1.25 U Native Pfu DNA Polymerase
(Stratagene) in 25 µl total reaction volume. The following two-step
PCR program was used: 3 min at 95 °C; 18 cycles of denaturation at
95 °C for 15 s and annealing and extension at 68 °C for 12 min.
Luciferase assays
RPTE or HT-1080 cells were grown in 12-well tissue culture-treated
plates to 60% conﬂuence. Fireﬂy luciferase constructs (pGL2-BKV
11J.R. Abend, M.J. Imperiale / Virology 378 (2008) 6–12strain) and a promoterless control Renilla luciferase plasmid (pRL-Null,
Promega) were cotransfected into RPTE cells at a ratio of 9:1, with a
total of 0.6 µg of DNA per well, using the Effectene Transfection
reagent (Qiagen) according to the manufacturer's recommendations.
TGF-β was added at 3 to 4 h post-transfection (hpt) and total cell
lysates were harvested at 48 hpt in 1× Passive Lysis Buffer (Promega).
Luciferase assays were performed on triplicate samples using the
Dual-Luciferase Reporter Assay (Promega), according to the manufac-
turer's recommendations. Results are expressed as relative light units
(RLU) of ﬁreﬂy luciferase activity normalized to RLU of Renilla
luciferase activity. TGF-β did not signiﬁcantly affect the levels of Re-
nilla luciferase activity (data not shown). Statistical signiﬁcance was
determined using a two-tailed Student's t test assuming unequal
variance, and P valuesb0.01 were considered signiﬁcant.
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